Implications of the Accuracy of MEPS Prescription Drug Data for Health Services Research
This paper assesses the quality of the Medical Expenditure Panel Survey (MEPS) drug data and the impact that misreporting prescription drug data has on descriptive and behavioral analyses. It does this by matching MEPS participants with Medicare Part D coverage during the period 2006-2007 to their Part D claims data. In the validation sample, the number of drug fills and total expenditures are reasonably accurate compared with claims. Household respondents tended to underreport the number of different drugs taken, but tended to overreport the number of fills of each drug. Behavioral analyses of the determinants of medication use and expenditures were largely unaffected because underreporting cut across most sociodemographic groups.
The Medical Expenditure Panel Survey (MEPS) is a unique, nationally representative source of micro data on health care use and expenditures for all payers. Household respondents report drugs and the number of times each drug was obtained, while followback surveys of pharmacies are the primary source of price and expenditure data. The validity of the data is critical because the MEPS is widely used for national estimates, behavioral modeling, and policy simulations, including many analyses of prescription drug markets.
Previous studies have found that MEPS respondents reported inpatient hospital stays well, but tended to underreport ambulatory services (office, hospital outpatient department, and emergency department visits) Olin 2009a, 2009b) . A validation study of the Medicare Current Beneficiary Survey (MCBS) found that Part D expenditures were underreported (Centers for Medicare and Medicaid Services [CMS] 2010). However, studies of the MEPS also suggest that biases introduced into behavioral and distributional analyses are likely small, and that simple adjustment strategies can correct effectively for underreporting.
We extend these previous studies to validate prescription drug use reported by household survey respondents and expenditures reported by pharmacies, using Medicare beneficiaries in the 2006 and 2007 MEPS who were linked to their Medicare administrative records. The analytic sample contains 1,271 observations of MEPS sample individuals who reported Medicare coverage and who had Medicare Part D drug coverage in the linked administrative data set for an entire year.
The Part D program began on January 1, 2006, and had 28 million enrolled Medicare beneficiaries in April 2010. Beneficiaries may obtain Part D coverage through either a prescription drug plan (PDP) or a Medicare Advantage plan. Medicare beneficiaries who also have Medicaid (''dual eligibles'') are automatically enrolled in a PDP. Enrollment is voluntary for other Medicare beneficiaries. Benefits for 2009 were budgeted at $53 billion.
The initial analyses of this sample assess: 1) the concordance between the number of drugs and prescription drug fills reported by the household in the MEPS and the numbers in the administrative data, and 2) the concordance between MEPS total drug expenditures and expenditures found in the Part D claims. We further investigate the personal and interview characteristics (such as self versus proxy response and interview language) associated with the level of concordance.
Next, we investigate whether reporting errors in the MEPS lead to systematic biases in behavioral analyses by estimating pairs of drug use regressions employing the claims and MEPS household-reported use measures, respectively, as the dependent variable and comparing the results. We formally test whether the marginal effects of each covariate are the same in the pairs of regressions. For example, does poor health increase drug spending by the same magnitude whether using the household-reported or claims-based measure?
Validation Literature
While the accuracy of other forms of service use in the MEPS has been the subject of validation studies, the accuracy of MEPS prescription drug data has been assessed by comparing aggregate estimates from the MEPS with other sources. In a linked study of MEPS and Medicare claims data, Olin (2009a, 2009b) found inpatient stays and number of inpatient nights were accurately reported. Respondents, however, underreported office visits by 19%, emergency department visits by 34%, and Medicare expenditures by 12%. Nonetheless, behavioral analyses were not likely to be significantly affected by misreporting. In particular, variation in underreporting across subgroups was small in magnitude even when statistically significant. Generally, the marginal effects from service use and expenditure regressions had the same sign and often similar magnitudes, except for racial and ethnic differences in expenditures.
Each year, MEPS estimates of prescription drug use and expenditures are compared with the National Health Expenditure Accounts (NHEA) and other sources, and periodically detailed comparisons reconcile differences between the MEPS and NHEA. The NHEA drug expenditure estimates are derived from pharmacy data collected by IMS Health, a market research firm; CMS program data; and the MEPS. Both Selden et al. (2001) and Sing et al. (2006) found that MEPS drug expenditures were 10% lower than those in the adjusted NHEA.
Validation studies of reported prescription drug use in other surveys typically find high accuracy, but variation across drugs. These studies compare surveys with pharmacy data (for example, Klungel et al. 2000; Monster et al. 2002; Paganini-Hill and Ross 1982; Poisal 2003 Poisal -2004 Sjahid, van der Linden, and Stricker 1998; Van den Brandt et al. 1991) and claims data (for example, Boudreau et al. 2004; Caskie and Willis 2004; Caskie et al. 2006; Curtis et al. 2006; CMS 2010; Haapae et al. 2010; Kwon et al. 2003; Metlay, Hardy, and Strom 2002; Nielsen et al. 2008) . In a study in the Netherlands, 67% of respondents reported currently using the same number and types of drugs found in the pharmacy data, with symmetric over-and underreporting of the number of drugs (Klungel et al. 2000) . In another Dutch survey, respondents reported using at some time 61.2% of drugs found in their pharmacy records in the last 2.5 years (van den Brandt et al. 1991) . Other studies have reported measures of agreement for drug classes and found that agreement varies greatly. For example, in an in-person survey of regularly or continuously used medicines in Denmark, kappas ranged from .39 to .82, indicating fair to almost perfect agreement, depending on the drug (Nielsen et al. 2008) . Most studies have focused on people with specific conditions or specific classes of drugs, or validated data collected for specific studies. CMS (2010) evaluated Medicare Part D expenditures in the MCBS. The total expenditures for the fills reported in the MCBS were 84% of the expenditures found in the claims data. In an older study of reported service in the MCBS, Poisal (2003 Poisal ( -2004 found, on net, respondents reported 82.3% of fills or refills found in pharmacy data, but 23% of respondents reported fills not found in the pharmacy data. In the U.S., apparent overreporting may reflect incomplete pharmacy data or free samples.
The results from the analysis of the MCBS may be the most relevant to the MEPS. The designs of the MCBS and MEPS are both based on the 1987 National Medical Expenditure Survey (NMES). Both surveys are in-person, longitudinal, have multiple interviews, and collect information about drug use through similar question structures. When asking about provider visits, both ask about drugs prescribed at those visits. Later in the interview both ask about other drugs not yet mentioned. In addition, the MEPS asks about free samples of drugs, and the MCBS prompts respondents with a list of drugs reported in prior interviews and asks about refills and prescriptions phoned in by a doctor to a pharmacy. Then both ask the number of times each drug was obtained since the last interview. The MEPS asks for permission to contact pharmacies to obtain payment information, while the MCBS, for purchases not covered by Part D, uses discounts off the average wholesale price (AWP). The AWP is a list price for drugs sold by wholesalers to retail pharmacies, so in practice it does not necessarily reflect what pharmacies pay for drugs. Another difference is that the MCBS samples individuals, who typically respond for themselves, and the MEPS uses one knowledgeable household respondent to report for all family members; more proxy responses may reduce accuracy.
The accuracy of drug use reporting varies with drug characteristics and the amount of drugs used. Accuracy is greater for maintenance drugs and for drugs for serious conditions, and lower for drugs used intermittently or as needed (Caskie and Willis 2004; Klungel et al. 2000; Monster et al. 2002; Nielsen et al. 2008) . Accuracy decreases with the number of drugs used (Van den Brandt et al. 1991 ) and the number of prescriptions filled (Poisal 2003 (Poisal -2004 .
Some health and sociodemographic factors are correlated with accuracy. Accuracy is lower for older people (Caskie et al. 2006; Curtis et al. 2006; Van den Brandt et al. 1991) , nonwhites (Curtis et al. 2006) , people in poor health (Caskie and Willis 2004) , and people with chronic conditions (Caskie et al. 2006) . Accuracy is greater for married adults than single adults (Caskie and Willis 2004; Haapae et al. 2010 ) and for those with higher income (Caskie and Willis 2004) . Scores on tests of memory and other cognitive abilities are not significantly associated with inaccuracy (Caskie and Willis 2004; Caskie et al. 2006) . Accuracy may be greater for adults with more education (Haapae et al. 2010) , but not when the analysis controls for cognitive ability (Caskie et al. 2006) . Generally accuracy is similar for men and women (Haapae et al. 2010; Van den Brandt et al. 1991) , but sometimes better for men (Caskie et al. 2006) .
In validation studies, recall periods are associated with accuracy. Accuracy is greater for six-month recall periods than for two-year recall periods (Boudreau et al. 2004 ). Accuracy falls with the time between the prescription and interview dates (Sjahid, van der Linden, and Stricker 1998) .
Sometimes drugs are reported in surveys and not found in claims data. This is a problem in studies using administrative data from U.S. plans and programs, such as a managed care plan (Caskie et al. 2006; Curtis et al. 2006) or the Veterans Administration (Metlay, Hardy, and Strom 2002) , and this discordance likely reflects drugs obtained elsewhere. Free samples were a minor reason for discordance in one study (Kwon et al. 2003) .
Methods

Data
The MEPS combines two overlapping panels of the U.S. noninstitutionalized civilian population to produce annual estimates (J. S. Cohen 1997 S. Cohen , 2003 . A new panel of households is sampled each year from the households that responded to the National Health Interview Survey, an address-based survey. Each panel uses five in-person interviews to collect two calendar years of data. During each interview, a single informant typically reports for all household members, regardless of age, and the average recall period is five months. The MEPS asks that this person be the family member most knowledgeable about health and health care use in the household. Additional information about payments for drug use reported by the household are collected in the follow-back Pharmacy Component (PC) survey.
Our validation data are from the Medicare program. The Medicare Part D Denominator files indicate the months that beneficiaries were enrolled in a prescription drug plan or a Medicare Advantage plan. The CMS Medicare Prescription Drug Event files contain drug claims from both types of plans.
Matching MEPS Beneficiaries to Medicare Administrative Records
We constructed a sample of MEPS Medicare beneficiaries matched to Medicare administrative data. We selected MEPS Medicare beneficiaries who were in the MEPS after Part D began (2006 and 2007) and for whom the MEPS obtained identification numbers that allowed us to match to administrative data (Panels 10 and 11). In these panels, MEPS respondents reported 4,955 household members had Medicare in 2006 and/or 2007, yielding 7,293 annual observations eligible for matching to CMS data. For our analysis, each calendar year a person had MEPS data (''person-year'') is an observation, because the MEPS is often used to create annual estimates. Medicare beneficiaries in the MEPS were asked to voluntarily provide their Medicare card number so their Medicare records could be located and used for statistical research purposes. Under a Data Use Agreement with CMS, beneficiaries in our full MEPS sample were matched to their Medicare enrollment and claims data using survey-reported Medicare health insurance claim numbers (HICNs) or Social Security numbers (SSNs). Complete HICNs or SSNs were reported for 3,383 person-years. Among them, 2,814 (39% of those eligible for matching) matched to the administrative data on three criteria: identification number, sex, and date of birth.
We adjusted the weights of the matched sample to reflect the Medicare Part D population.
A logistic regression found that MEPS Medicare beneficiaries who matched to CMS data were more likely to be the household informants (self-respondents), to report their race as white compared with nonwhite, to have completed high school, and to have at least one prevalent, chronic condition compared with the Medicare beneficiaries who did not match exactly or provide their HICN or SSN for the matching (full results are available in an appendix table available from the authors). We used a propensity-score reweighting procedure based on this regression to adjust the standard MEPS weights for differences in the number of chronic conditions and sociodemographic and interview characteristics in the likelihood of matching to CMS enrollment files. Applying the adjusted weight, we found no statistically significant differences in expenditures, and differences in survey-reported drug use between the matched and unmatched samples diminished but were not eliminated. Specifically, prior to reweighting, beneficiaries in the matched sample acquired an average of 7.0 drugs, compared with 5.7 drugs for the unmatched sample. Reweighting reduced the difference from 1.3 to .8 drugs, and both differences were statistically significant at the .01 level. The difference in number of fills was 5.1 before reweighting and 2.4 (7% of the mean) after, and the significance fell from the .01 to the .10 level.
Analytic Sample
Prescription drug claims data were available only for beneficiaries enrolled in Part D. To describe accuracy over the course of a calendar year, which is the time period most analysts use, we restricted the sample to beneficiaries with Part D in all 12 months according to the CMS enrollment data. We excluded 1,019 person-years with no Part D coverage, 475 with one to 11 months of coverage, and 21 who were institutionalized part of the year, leaving 1,299 person-year observations. Part D claims data exclude drugs provided by federal pharmacies, particularly the Veterans Administration, so we excluded 28 person-years for which the sampled person reportedly obtained medications from federal pharmacies. 1 The final analytic sample contains 1,271 person-years.
Measures of Medication Use and Expenditures
In each interview, MEPS respondents are asked for the names of medications obtained during the reference period. The interviewers tell them that looking at the bottles, containers, tubes, or bags would be helpful. Interviewers enter the names and supplementary information (such as strength) from the labels or as reported by the respondent verbatim. To the extent feasible given the information from the household, coders classify the drug by drug class, drug subclass, active ingredient or compound, dosage form (for example, tablet), and strength using the Generic Product Identifier code produced by Wolters Kluwer Health, Inc. (2005) . Respondents also report the number of times each drug was obtained.
Payment data generally are obtained from pharmacies. Households are not expected to accurately and patiently report payments and other details for each prescription filled and refilled, unless they report submitting drug claims to their insurers for reimbursement. The process for merging the pharmacy payment data onto the household-reported drugs and editing the data is described in Moeller et al. (2001) . Not all sample members, however, sign permission forms to contact their pharmacies, and not all pharmacies respond. In 2007, 55.2% of sample members who reported obtaining medications had pharmacy data. When pharmacy data are missing for a person's drug, generally the payment data are imputed from the pharmacy data for another person's purchase of the same drug. We evaluate the validity of the expenditure data collected and imputed because these are the data used by analysts; thus we do not evaluate solely household or pharmacy expenditure reports. Recent research led to improved procedures for editing the price data, which were first implemented with the 2007 data (Zodet, Hill, and Miller 2010) . For this study, the 2006 data were reedited to reflect these changes, and therefore this study analyzes the quality of the current MEPS data. 2 To ensure comparability, we exclude some drugs from both the MEPS and claims data. Part D specifically does not cover certain drugs, such as barbiturates, over-the-counter drugs, and nearly all vitamins and minerals. A few pharmacy items, such as glucosemonitoring supplies, are covered by Part B, not Part D. In rare situations, Part D pays for drugs in the hospital, so we use the reported dates that hospital stays began and ended to remove some drugs from the claims data. 3 We also exclude insulin and syringes because the MEPS collects information about these pharmacy items somewhat differently from other items.
We examine the number of distinct drugs, number of fills, total expenditures, and thirdparty payments. 4 For both MEPS and claims data, we count the number of distinct drugs purchased during the calendar year, where we define drug as the active ingredient or compound. For example, if a person obtains the brand name and generic for the same active ingredient, that is one drug. If a person obtains both the regular drug and the extended-release version, that is one drug. We count the number of fills in the claims data as the number of claims. In the MEPS, we sum across drugs the number of times each drug reportedly was obtained during the calendar year. 5 We focus on third-party payments, rather than Medicare payments, because pharmacy reported third-party payers may differ from Medicare when there is a subsequent reconciliation between the plan and another program, such as a state pharmacy assistance program or Medicaid.
Control Variables
We created the following sociodemographic variables from the MEPS. Age was categorized as under 65, 65 to 74, 75 to 84, and 85 and older. Binary indicators represented the following categories: female, nonwhite, Hispanic, married, and living in a metropolitan statistical area (MSA). Region was categorized as North, South, Midwest, and West. Family income was coded as below 100%, 100% to 199%, and 200% or more of the federal poverty line (FPL). Education was categorized as ,12 years, 12 years, and .12 years. There were five categories of perceived health: excellent, very good, good, fair, or poor. Binary indicators represented one, two, or three or more prevalent, chronic conditions (active asthma, diabetes, emphysema, high blood pressure, high cholesterol, ischemic heart disease, stroke, and arthritis or joint pain). A cognitive limitation indicator was coded ''1'' for people who experienced confusion or memory loss, had problems making decisions, or required supervision for their own safety. An activity limitation indicator was coded ''1'' if the person received help or supervision with any activities of daily living (ADLs) or instrumental activities of daily living (IADLs) ''because of impairment or physical or mental health problem.'' Medicaid was coded ''1'' if the person had Medicaid coverage any time during the year. Private drug coverage was divided into coverage through an employer or union or other private coverage any time during the year.
We also constructed indicators describing the interviews and how utilization data were obtained for each beneficiary. Interview language was classified as entirely in English or as having at least one MEPS interview in a language other than English. We classified reporting of drug use data into one of three categories: self-reported, indicating that the sample beneficiary was the household informant in the last interview (68% of the final matched sample); household proxy (30%), indicating that use data were reported by a proxy living in the household (usually a spouse); and nonresident proxy, indicating that a person outside of the household reported use data for the sampled person (2%). We classified use of bottles or receipts as memory aids into three categories: all interviews (59%), some interviews (33%), and no interviews (7%). We identified the maximum recall period across the three interviews that obtained information for each calendar year. We classified this recall period as either six months or less (45%) or seven or more months (55%). Finally, year in survey was coded ''0'' for the first year and ''1'' for the second year in the MEPS. Because the analytic sample uses both years of Panel 11 and the second year of Panel 10, 71% of the sample is in the second year.
Analyses
We examined survey data compared with claims for drug use and expenditures in our matched analytic sample. We calculated univariate means for annual utilization at the person-year level and the ratio of the mean utilization reported in the MEPS and the mean recorded in claims. T-tests were used to examine differences in means between the MEPS and claims measures. Our drug use and expenditure measures are continuous, so we calculated Lin's concordance correlation coefficient, which is scaled from 21 for perfect disagreement to +1 for perfect agreement (Lin 1989) . 6 We then conducted bivariate analyses of the utilization means, ratios, and concordance correlation coefficients by sociodemographic and interview characteristics, using adjusted Wald statistics to test for differences.
We investigated whether reporting errors in the MEPS lead to systematic biases in behavioral analyses. To do this, we estimated pairs of utilization regressions using the claims and MEPS household-reported utilization measures, respectively, as the dependent variable and comparing the results. The independent variables in each pair included an identical set of sociodemographic covariates often used in models of health care utilization (Aday and Andersen 1974) . Negative binomial count data regression models were estimated for the number of drugs and number of fills. To account for the skewed distributions of expenditures, generalized linear models (GLMs) with square root links and Poisson distributions were estimated for total drug expenditures. Hill and Miller (2010) found the square root link fits the distribution of drug expenditures in the MEPS well. We report marginal effects from the regression models in order to compare the magnitude of effects in each pair of regressions. We formally tested whether the effect of each covariate is the same in the pairs of regressions. For example, does poor health increase the expenditures by the same magnitude whether using the household-reported measure or the claims-based measure? Because coefficient estimates and the marginal effects are interpretable as random variables, the comparison of marginal effects is analogous to a pairwise t-test of the means of two (correlated) random variables.
All analyses used the adjusted MEPS sampling weights to compensate for differences between the matched and unmatched samples and to account for the stratified and clustered (at the primary sampling unit level) design of the MEPS survey. Accounting for geographic stratification and clustering also corrects for clustering at the household and individual levels (Williams 2000) , and in particular the clustering that occurs because household-reported and claims-based measures of utilization were estimated using the same matched sample of beneficiaries.
Results
Table 1 compares mean utilization based on claims and the MEPS for our matched sample. There was no difference in the proportion of beneficiaries reporting any prescription drug use, with an agreement rate of .97 (95% Confidence Interval[CI]: .96-.98) and a k statistic of .66, indicating ''substantial'' agreement (Landis and Koch 1977) .
Agreement was lower for annual counts of the number of drugs. Mean number of drugs reported in the MEPS was 6.5, compared with 8.5 in the claims for the analytic matched sample (Table 1) , a difference of 23%. As measured by Lin's concordance correlation coefficient, overall concordance between the MEPS and claims number of drugs at the person-year level was good: .71 on a scale from 21 to 1. To better understand the discrepancies, for each person-year we matched the drugs reported by the household with those found in the claims. 7 The drugs that did not match were more likely to have short-term uses. Anti-infectives, topical agents, and pain medications accounted for 53% of the drugs found in the claims data but not in the MEPS, and accounted for only 23% of the drugs that matched. In addition, the drugs that matched were filled an average of 5.5 times during the year, compared with two times for those in the claims but not in the MEPS. Fewer fills were consistent with the unmatched drugs being for short-term use.
There was greater concordance for the number of fills or refills. Mean number of fills reported in the MEPS was 37.4, compared with 38.2 in the claims for the analytic matched sample (Table 1) , a difference of 2%. As measured by Lin's concordance correlation coefficient, overall concordance between the MEPS and claims reported number of drugs at the person-year level was very good: .81. Two factors account for greater agreement in the number of fills than the number of drugs. First and most importantly, MEPS respondents reported more fills for each drug they reported than were found in the claims data. 8 Free samples could be a reason that MEPS respondents reported more fills than were found in the claims data, but the respondents were not asked to report the number of free samples obtained, so the contribution of free samples cannot be quantified. Second, underreported drugs typically were used intermittently, so there were fewer fills in the claims data for the underreported drugs than the matched drugs. Total prescription drug expenditures also had good concordance between the two sources. Mean annual expenditures in the MEPS were $2,426, compared with $2,331 in the claims data, a difference of 4% (Table 1) .
As measured by Lin's statistic, overall concordance between the MEPS and claims total expenditures at the person-year level was good: .78. The distributions of drug expenditures were also quite similar for the two measures (Figure 1) . Two factors account for mean MEPS expenditures somewhat exceeding expenditures from the claims data. First, when a pharmacy does not provide thirdparty payment information to the MEPS, the amount imputed during the editing process tends to be high for generics. For low-cost generics, it can be difficult to distinguish pharmacy reports in which the household paid the full amount from pharmacy reports in which a third-party payment was missing, which can lead to unnecessary imputation of third-party payments. Second, mean annual claims-based expenditures for the drugs Notes:
Marginal effects are from negative binomial regressions. All estimates were weighted using the propensity score-derived weight for the matched sample. All standard errors and statistical tests account for the clustered and stratified design of MEPS using Taylor series linearization. N51,271.ADLs found in both the MEPS and claims data were $348, compared with $100 for the drugs not found in the MEPS, so the effect of underreporting is minor. Third-party payments had good concordance between the two sources. Mean annual third-party payments in the MEPS were $1,832, compared with $1,900 in the claims data (Table 1) , a difference of 4%. As measured by Lin's statistic, overall concordance between the MEPS and claims total expenditures at the person-year level was good: .79. Medicare payments were lower than third-party payments in the MEPS because when a household did not report Part D coverage and the third-party payment was imputed, the payment was not imputed to Medicare, but instead to a different source. Hence, MEPS mean annual Medicare expenditures were 11% lower than those from the claims data.
Correlates of Accuracy
We examined how the accuracy of medication use and expenditures in the MEPS varied with important sociodemographic, health status, and interview characteristics. The main findings were: all socioeconomic groups tended to underreport drugs, and most socioeconomic groups accurately reported the number of fills or refills. Table 2 provides detailed comparisons of total drug expenditures, for which accuracy varied across several personal and interview characteristics.
The accuracy of total drug expenditures ( Table 2) varied across the age distribution, with greatest accuracy, measured by Lin's concordance correlation coefficient, among Medicare beneficiaries ages 65 to 74. Expenditures were more accurate in the Midwest than other regions. Beneficiaries with no chronic conditions had lower concordance in their total drug expenditures. Families below the poverty line and those enrolled in Medicaid had lower total drug expenditures in the MEPS than were found in the claims data.
Patterns of drug use were strongly associated with accuracy. Those who had fewer drugs and fills in the claims data had greater expenditures in the MEPS than in the claims data, which is due to these households reporting more fills than were found in the claims data, on average. In contrast, those who had more drugs in the claims data had lower expenditures in the MEPS than in the claims data because these households were more likely to underreport both drugs and fills. Those who reported they obtained any free samples had higher expenditures in the MEPS than the claims data. Because the MEPS household interview does not ascertain how many fills were free samples, all reported fills receive a positive price in the editing process. Hence, some beneficiaries who obtained free samples may have had overly high expenditures.
Shorter recall periods and use of prescription bottles or receipts during interviews were both associated with greater accuracy, but the accuracy of expenditures did not vary significantly with other interview characteristics.
Use and Expenditure Regressions
Rather than use multivariate regressions to estimate the independent effects of each covariate on reporting accuracy, we assess the impact of reporting error in typical behavioral analyses of health care use and expenditures. Thus we investigate whether reporting error systematically affects estimates of the contribution of factors likely to explain use and expenditures. Table 3 reports the results of pairs of regressions of the determinants of prescription drug use based on MEPS householdreported measures and claims measures, respectively, as the dependent variable and the same set of covariates from the matched sample. The first set of columns shows the marginal effects from the number of drugs regressions. There were marked gradients in perceived health status and number of chronic conditions, with no differences in the marginal effects for perceived health but a stronger gradient for number of chronic conditions in the claims-based measure of number of drugs. Differences were mainly in insurance status. The effect of Medicaid coverage was larger for the claims-based number of drugs (1.90) than the MEPS number of drugs (1.05, p 5 .030). The MEPS-claims difference was larger for the effect of reported employment-related insurance on number of drugs (.40 versus 1.72, p 5 .035). Using the claims data, Hispanics were associated with .01 fewer drugs, but using the MEPS measures, the effect was 1.00 fewer drugs (p 5 .083). The effects of income were small and statistically insignificant in both models, but the signs were reversed and the differences were statistically significant at the 10% level.
The second set of columns in Table 3 shows the marginal effects from the number of fills or refills regressions. Again, there were marked gradients in perceived health status and number of chronic conditions, with similar marginal effects in both the MEPSreported and claims measures. Unlike the number of drugs regressions, differences in magnitudes of the effects of insurance coverage on number of fills or refills were not statistically significant. Like the number of drugs regressions, the effects of income were small and statistically insignificant in both models, but the signs were reversed and the differences were statistically significant. For example, in the MEPS, income more than twice the poverty line was associated with 2.9 additional fills, compared with 2.2 fewer fills in the claims data ( p 5 .015). Table 4 reports the results for pairs of regressions of the determinants of prescription drug expenditures based on the MEPS and claims measures. Perceived health status and number of chronic conditions were associated with higher expenditures in both sets of marginal effects, and while the pattern was the same, there were differences between the estimates. The MEPS estimates of the effects of good, fair, and poor health were greater than their claims-based counterparts (1,151 v. 842, p 5 .041; 1,453 v. 1,024, p 5 .014; 2,809 v. 2,251, p 5 .078). The effect of having one chronic condition (compared to none) was statistically significant in the claims-based results, but not in the MEPS results. Both sets of marginal effects indicated that elderly beneficiaries had lower expenditures than those under age 65, but the negative effect of ages 65 to 74 was larger and statistically significant in the claims-based results. The geographic effects varied modestly between the sets of results: the effect of residing in an MSA was statistically significant in the MEPS results, but not the claims-based results, while the reverse was true for the effects of the South and West. The effects of insurance and interview language varied. The effects of Medicaid and employment-related drug coverage were larger in the claims data (547 v. 945, p 5 .027; 88 v. 590, p 5 .016).
Discussion
Our comparisons of household-reported prescription drug use to Medicare Part D claims in the matched analytic sample found that household respondents in the MEPS were good at reporting the number of fills and refills. They tended to overreport the number of fills per drug, but underreported the number of drugs. Consistent with other validation studies of reported drug use, we found that the drugs not reported typically have short-term or intermittent uses (antiinfectives, topical agents, and pain medications), rather than being maintenance drugs that are generally captured well. On average, MEPS respondents reported on drug use over a five-month period, so drugs that were used early in the reference period could be forgotten at the time of the interview. MEPS measures of total expenditures on drugs were close to the Part D claims data, both on average and across the distribution of expenditures. This facilitates studies modeling the distributions of drug expenditures. Generally, marginal effects from drug use and expenditure regressions had the same sign and often similar magnitudes.
We note three potential limitations in our comparisons of the MEPS to Medicare claims. First, we matched a large sample of Medicare beneficiaries in the MEPS to claims data, but our matched sample itself is not nationally representative of Medicare beneficiaries. However, we note that our matched sample mirrors expenditures by the full sample of Medicare beneficiaries in the MEPS when using weights adjusted for differential matching. Second, we examined Medicare beneficiaries only, and our findings may not generalize to other family members of Medicare beneficiaries or to the rest of the U.S. population residing in households with no Medicare beneficiaries. Elderly and disabled Medicare beneficiaries use substantially more health care services than other Americans (Ezzati-Rice, Kashihara, and Machlin 2004), and a previous study and results presented here suggest that underreporting is greatest among higher-use groups (Poisal 2003 (Poisal -2004 . To this extent, our findings may provide an upper bound estimate of underreporting for the full MEPS sample. The elderly and disabled Medicare populations differ in other important ways from the rest of the population, but it is unclear how this would affect the accuracy of prescription drug use and expenditures. Third, starting with Panel 12, after our study, MEPS bilingual interviewers can toggle between English and Spanish questions, rather than translate the questions themselves, which may improve the accuracy for many non-English language interviews.
The accuracy of medication use and expenditures in the MEPS compares well with the accuracy of other types of health care use collected in the MEPS. It is similar to the high levels of concordance found between the MEPS and Medicare claims data for inpatient hospital stays and more accurate than reporting of either office visits (19% underreported) or emergency department visits (49% underreported) Olin 2009a, 2009b) . The accuracy of medication use and expenditures in the MEPS also compares favorably with the accuracy of medication use collected in other surveys. In the MEPS, the number of fills was underreported by 2%, on average, compared with 17% in the MCBS (Poisal 2003 (Poisal -2004 prior to 2006. Similarly, drug expenditures in the MEPS exceeded expenditures in the claims by 4%, on average, and MCBS expenditures were 16% less than expenditures in claims data. In the MEPS, we found households reported very few medications not found in the claims data. Like the MCBS, underreporting in the MEPS was higher among beneficiaries who obtained more fills and refills. While the MCBS and MEPS are similar surveys, the results may not be fully comparable because we studied beneficiaries in the Part D program, whereas Poisal studied all Medicare beneficiaries before Part D began. After the Part D program started, the MCBS used the Part D claims, rather than household reports, to measure use and expenditures covered by Medicare, and survey reports for use covered by other payers. Like Van den Brandt et al. (1991) , we found accuracy decreased with the number of drugs used. Like Caskie and Willis (2004) and Caskie et al. (2006) , we found cognitive ability did not affect reporting, but the household respondent likely reported for the more severely impaired sampled individuals. We also found, like Caskie and Willis, that accuracy increased with income.
Our results suggest that the MEPS is a good data source for prescription drug use and expenditures. While some types of shortterm and intermittently used drugs were underreported, maintenance drugs generally were reported accurately, suggesting the MEPS is well-suited for studies of people with chronic conditions. Research to improve the reporting, editing, and imputation of medication data will continue to be an area of emphasis with the MEPS. For example, if the sample size were sufficient, a potential extension of this paper could assess how reporting affects measures of drug adherence.
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Benjamin Lê Cook and two anonymous referees provided helpful comments on drafts of this paper. Blaine Byars provided expert programming assistance with the MEPS. This paper was presented at these conferences: the American Society of Health Economists 2010, the Joint Statistical Meetings 2010, and Health Survey Research Methods 2011. The views expressed in this paper are those of the authors, and no official endorsement by the U.S. Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services is intended or should be inferred.
1 The MEPS does not attempt to ask respondents to report which drugs were obtained at each pharmacy. 2 Additionally, the drug data from both years were reedited to reflect other minor changes implemented in the 2008 editing process.
3 Inpatient drug use is not collected separately in the MEPS, but is included in total inpatient expenses. 4 Our analysis uncovered an editing error that affects the ability to assess concordance in outof-pocket drug expenditures. When the pharmacy reported zero out-of-pocket payments and the third-party payments were missing, the fill was treated as if all the payment data were missing; thus all the payments, including the out-of-pocket amount, were imputed, and hence were likely to receive positive imputed amounts. In fact, zero copays can be found in the matched claims data. Due to this data processing problem, mean annual out-ofpocket payments for drugs were higher in the MEPS than in the claims data. The editing error was corrected for the 2009 and subsequent MEPS data.
5 This sum reflects imputed acquisitions when the number of fills was not provided by the household or in the rare cases when a pharmacist determined that the reported number of acquisitions during the reference period was implausibly large. Using matched data at the person-reference period drug level, we found these determinations were overwhelmingly correct. 6 Lin's concordance correlation coefficient combines measures of precision and accuracy for continuous variables.
7 Because households do not always provide details about the drugs they use, this matching allowed matches on drug group, drug class, or name when there was no match on the specific drug. 8 Some of these overreports were outliers in the fills for that type of drug, and the criteria used to identify potential outliers for pharmacist review were expanded slightly for the 2009 and subsequent MEPS data. However, changing those criteria will have minimal effect on total fills and expenditures.
